Modified vaccinia ankara virus variant
AssigneeBavarian Nordic A/S
InventorsPaul Chaplin, Paul Howley, Christine Meisinger
Life of this patent
Estimating the term…
Abstract
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen.
Claims13
In a method for immunizing an animal, including a human, with a vaccine, the improvement comprising:
- administering in combination with said vaccine a composition comprising an MVA-BN vaccinia virus, which virus is characterized by replicating in vitro in chicken embryo fibroblasts and by being non-replicative in vitro in human cell lines selected from the human keratinocyte cell line HaCaT, the human embryo kidney cell line 293, the human bone osteosarcoma cell line 143B, and the human cervix adenocarinoma cell line HeLa.
In a method for immunizing an animal, including a human, against a heterologous antigen, the improvement comprising:
- administering in combination with said heterologous antigen a composition comprising an MVA-BN vaccinia virus, which virus is characterized by replicating in vitro in chicken embryo fibroblasts and by being non-replicative in vitro in human cell lines selected from the human keratinocyte cell line HaCaT, the human embryo kidney cell line 293, the human bone osteosarcoma cell line 143B, and the human cervix adenocarinoma cell line HeLa.
In a method for immunizing an animal, including a human, with a vaccine, the improvement comprising:
- administering in combination with said vaccine an adjuvant composition comprising an MVA-BN vaccinia virus, which virus is characterized by replicating in vitro in chicken embryo fibroblasts and by being non-replicative in vitro in human cell lines selected from the human keratinocyte cell line HaCaT, the human embryo kidney cell line 293, the human bone osteosarcoma cell line 143B, and the human cervix adenocarinoma cell line HeLa.
Dependencies are inferred from the claim text.